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Doxorubicin (DOX) is an anthracycline antibiotic used for anticancer therapy. However, this agent can
cause various systemic side effects including cognitive impairments in chronic use. Brain damage due to
DOX is caused by an increase of tumor necrosis factor-alpha (TNF-a) level in the brain. Increased TNF-a
can further lead to chronic inflammation which can lead to neuronal deaths or neurodegenerative dis-
eases. Mangiferin (MAG), a compound extracted from Mangifera indica, has been found neuroprotective
activities, but its effect on DOX-induced brain damage is unknown. This study aims to determine the
effect of MAG on brain damage induced by DOX. Male Sprague-Dawley rats were induced by DOX
intraperitoneally. MAG was given orally at the doses of 30 and 60 mg/kg bw for 7 consecutive weeks. The
parameters measured were inflammatory and oxidative stress markers in brain tissue. Coadministration
of MAG with DOX reduced inflammation which was marked by the reduction of TNF-amRNA expression,
decreased TNF-a level and reduction of oxidative stress marked by increase of superoxide dismutase
level and decrease of malondialdehyde level. In conclusion, MAG was shown to have a neuroprotective
effect on brain damage induced by DOX, partly due to inhibition of inflammation and oxidative stress.
Copyright © 2016 Institut Pertanian Bogor. Production and hosting by Elsevier B.V. This is an open access
article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Doxorubicin (DOX), an anthracycline antibiotic, is widely used
for anticancer agent, including breast cancer, cancer in children
such as Wilms tumor, soft tissue sarcomas, also Hodgkin’s and non-
Hodgkin’s lymphoma (Hortobagyi 1997). Despite having a wide
anticancer effect, the utilization of DOX can cause side effects
manifested as heart cell damage (Hortobagyi 1997) and cognitive
disorders (Tannock et al. 2004). Cognitive disorders may decrease
daily activity performances, such as work performances, access to
health service, and interaction and awareness to family members
(Janelsins et al. 2011). Long-term research on DOX-based chemo-
therapy showed that 76% of patients experienced cognitive degra-
dation on acute phase, and 61% of patients experienced cognitive
degradation on a low phase (Wefel et al. 2010).l).
nian Bogor.
r. Production and hosting by ElsAlthough the biochemical basis for these cognitive problems is
unknown, it has been demonstrated that cancer therapeutics
agents such as DOX can modulate endogenous levels of cytokines
such as tumor necrosis factor (TNF) alpha (Usta et al. 2004). In
addition, enhanced circulating TNF-a can initiate local TNF pro-
duction via activation of glial cells leading to production of reactive
oxygen or nitrogen species (Szelenyi 2001). DOX causes an increase
of peripheral TNF-a (Tangpong et al. 2006; Aluise et al. 2010;
Gilliam et al. 2011). The increase of peripheral TNF-a is caused by
raised TNF-a production by heart muscles (Mukherjee et al. 2003)
and immune cells (Ujhazy et al. 2003). The increase of TNF-a in
brain tissue may most likely be caused by receptor uptake at the
blood-brain barrier (Osburg et al. 2002) and activation of glia which
causes increased production of local TNF-a through signal activa-
tion of nuclear factorekappa B (NF-kB) (Mohamed et al. 2011;
McCoy and Tansey 2008). Further escalation of TNF-a can induce
mitochondrial damage (Tangpong et al. 2006; Joshi et al. 2005) and
constant glia activation, which in turn play roles in chronic
inflammation that can lead to neuronal deaths or neurodegenera-
tive diseases (Gonzales-Scarano and Baltuch 1999). Thus, it isevier B.V. This is an open access article under the CC BY-NC-ND license (http://
Table 1. Gene-specific primer sequences used in RT-PCR
Gene Primer sequence PCR product
TNF-a F: 5’ e TCT CAA GCC TCA AGT AAC AAG C e 3’ 330 pb
R: 5’ e ATG AGG TAA AGC CCG TCA GC e 3’
b-actin F: 5’ e TGT TGT CCC TGT ATG CCT CT e 3’ 222 pb
R: 5’ e TAA TGT CAC GCA CGA TTT CC e 3’
RT-PCR ¼ reverse transcription polymerase chain reaction.
Primer sequences used were referred to previous publication by Mohamed et al.
(2011).
S. Siswanto, et al52possible that an increase in TNF-a level may be a link between DOX-
induced oxidative stress and central nervous system injury.
Mangiferin (MAG) is a xanton glycoside, initially isolated from
Mangifera indica L, which is found in many types of mango trees. A
particular species of mango tree that grows in Indonesia,Mangifera
foetida Lour. (Anacardiaceae; locally called bacang), has been proved
to contain higher levels of MAG compared with other mango va-
rieties. MAG is a potent antioxidant (Pal et al. 2013), with hep-
atoprotective (Das et al. 2012) and neuroprotective (Liu et al. 2013)
activities. Our recently published studies showed that MAG also has
cardioprotective effects, especially on DOX-induced rats, by regu-
lating the intracellular calcium homeostasis (Arozal et al. 2015;
Agustini et al. 2015). MAG has also been found to decrease
inflammation and cell damage in the brain through the decrease of
TNF-a and negative regulation of NF-kB (Marquez et al. 2012). The
neuroprotective effect of MAG has also been studied on diabetic rat
model by delivering the mentioned MAG dosage for 8 weeks (Liu
et al. 2013).
To the best of our knowledge, there has not been any research on
the effect of MAG toward brain damage induced by DOX. The focus
of the present study was to understand the potential protective
effect of MAG to prevent brain damage induced by DOX as an effort
to enrich the use of evidence-based Indonesian natural herbal
medicine.
2. Materials and Methods
2.1. Materials
Unless otherwise stated, all reagents were of analytical grade
and purchased from Sigma-Aldrich (Singapore) or Merck Millipore
(Jakarta, Indonesia). DOX hydrochloride injection was obtained
from Kalbe Pharma (Jakarta, Indonesia). MAG was of analytical
grade and obtained from Plamed Science Technology Company (Xi-
an, China). RNA isolation, cDNA synthesis and reverse transcription
polymerase chain reaction (RT-PCR) kits were purchased from
Roche (Jakarta, Indonesia).
2.2. Animals
Study animals used were male Sprague-Dawley rats aged 12e16
weeks weighing about 180e200 g obtained from Badan Pengawas
Obat dan Makanan, Jakarta, Indonesia. Rats were kept in a room
with constantly-controlled temperature (21C) and humidity (55%)
with a 12 hour light/ dark cycle. They were allowed free access to
standard laboratory food and water. The protocol has been
approved by Animal Care Committee from Ethics Committee, Fac-
ulty of Medicine, Universitas Indonesia, Jakarta, Indonesia.
2.3. DOX and MAG preparation
To prepare DOX, a certain volume of DOX (supplied as 2 mg/mL
of DOX in saline 0.9%) was extracted from the original product vial
using syringe in a fume hood. No dilutionwas needed. MAG 60 mg/
kg bw was prepared by mixing 200 mg of MAG powder with 10 mL
of 0.5% sodium carboxymethyl cellulose (CMC) using mortar and
pestle until MAG was perfectly suspended (Arozal et al. 2015). MAG
30 mg/kg bw was prepared using the same procedure, except the
amount of MAG powder used was 100 mg.
2.4. Experimental design
Dosing and schedule of the study were determined according to
our previous study (Arozal et al. 2015) with some adjustments.
Previously, higher dose of MAG (100 mg/kg bw/day) had been
proven to give negative results. Hence, for this study theMAG doses
were decreased to 30 and 60mg/kg bw/day. Dosing and schedule of
DOX treatment were selected according to thework of Ibrahim et al.
(2009), where cumulative dose of15 mg/kg bw of DOX divided insix injections within 2 weeks was able to induce cardiotoxicity in
rats.
After 2 weeks of acclimatization, rats were randomly divided
into four groups consisting of five rats each. The groups were as
follows: normal group (control) which only received CMC 0.5% and
saline (vehicles), toxic control group (DOX) which only received
DOX, and two MAG groups which received both DOX and MAG
(both groups received DOX with the same dose as DOX group; DOX
þ MAG30 group was given MAG 30 mg/kg bw/day and DOX þ
MAG60 group was given MAG 60 mg/kg bw/day). MAG was given
orally every day for 7 consecutive weeks in CMC 0.5% as vehicle.
DOX was given intraperitoneally with a total dose of 15 mg/kg bw
divided in six injections with saline 0.9% as vehicle, starting from
the beginning of second week until the end of third week.
Throughout the experiment, rats were monitored closely for
signs of toxicity and mortality. Rats were weighed every day. At the
end of the seventh week, rats were sacrificed by cervical dislocation
method. Brains (the whole cerebrum in both right and left hemi-
sphere) were extracted then rinsed with cold 0.9% normal saline.
The brains were subsequently froze at 80C before undergoing
biochemical and molecular examinations.
2.5. Total RNA isolation
Brain tissue was homogenized using Ultra Turrax electric ho-
mogenizer. Total RNA was isolated from brain homogenate using
Tripure Isolation Reagent (Roche) according to the manufacturer’s
protocol. The isolated total RNA concentration and purity were
measured spectrophotometrically at 260 nm using Nanodrop 2000
(Thermo Scientific, Wilmington, USA). Only the samples with suf-
ficient purity (A260/280 > 1.8) were subjected to the next treatment.
2.6. cDNA synthesis
cDNA synthesis reaction was performed using Transcriptor First
Strand cDNA Synthesis Kit (Roche). The resulted cDNA concentration
and purity were measured spectrophotometrically at 260 nm using
Nanodrop 2000 (Thermo Scientific).
2.7. Examination of TNF-a mRNA Expression
RT-PCR was conducted using the FastStart Essential DNA Green
Master (Roche) kit on LightCycler Nano (Roche). Primers used for
amplification are presented on Table 1. The relative quantification
calculation of target mRNA was based on the expression of b-actin
mRNA as a comparator. Amplification was performed in 45 cycles
followed by melting curve analysis. Number of cDNA templates
used were 250 ng and the primary concentration used was 0.4 mM.
The amplification conditions for each gene were as follows: b-actin
(predenaturation: 95C for 10 minute, denaturation: 95C for 10
seconds, annealing: 53C for 10 seconds, elongation: 72C for 23
seconds) and TNF-a (predenaturation: 95C for 10 minute, dena-
turation: 95C for 10 seconds, annealing: 60C for 30 seconds,
elongation: 72C for 1 second).
After RT-PCR, the amplification product underwent electro-
phoresis on 2% agarose gel stained with SYBR Green for band
analysis. Only the amplification products that showed one band
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expression were quantified based on 2DDCT method (Livak and
Schmittgen 2001).2.8. Production of brain homogenates for determination of
TNF-a level, lipid peroxides, and superoxide dismutase (SOD)
Activity
The whole cerebrum tissues were cut and weighted 100 mg
then put into a glass mortar. The tissues were suspended with PBS
nine times volume of the brain tissue weight and 5 mL of protease
inhibitor solution (Sigma) was added for every 100 mg of tissue.
This mixture was then homogenized by using mortar and pestle.
The homogenate was then centrifuged at 10,000 g for 15 minutes
at 4C, then supernatant was taken. Supernatant was used for
measuring protein level, TNF-a level, malondialdehyde (MDA) level
and SOD activity.2.9. Measurement of protein level
Protein level was measured using Bradford (Sigma-Aldrich)
method and measured with spectrophotometer at wavelength of
595 nm.2.10. Determination of TNF-a level
Measurement of TNF-a level was conducted using ELISAmethod
using ELISA TNF-a kit for rat tissue (Sigma-Aldrich).2.11. Determination of SOD activity
SOD (Cu, Zn and Mn) activity was measured based on epinefrin
autooxidation inhibition rate (Misra and Fridovich 1972).2.12. Determination of lipid peroxides
MDA, a measure of lipid peroxidation in serum and brain tissue
was determined by reacting MDAwith TBA in an acidic atmosphere
and measured at wavelength of 532 nm (Abdel-Wahab et al. 2003).
Results were expressed in nmol/mg protein.2.13. Statistical analysis
The data obtained were analyzed using statistical program SPSS
Version 19. One-way analysis of variance was used for comparison
among groups, followed by post hoc test using Tukey. p < 0.05 was
considered to be significant.Figure 1. Effect of mangiferin (MAG) on doxorubicin (DOX)-induced alteration of brain
tumor necrosis factor (TNF)-a mRNA expression levels. mRNA expression levels are
normalized to b-actin as housekeeping gene. Values are presented as mean ± standard
deviation, ap < 0.05 versus the normal group; bp < 0.05 versus the DOX group. Normal
¼ normal group, DOX ¼ doxorubicin 15 mg/kg bw, DOX þMAG30 ¼ DOX 15 mg/kg bw
and MAG 30 mg/kg bw, DOX þ MAG60 ¼ DOX 15 mg/kg bw and MAG 60 mg/kg bw.3. Results
At the first week of experiment, stable increase of body weight
was observed in all groups. However, in all groups receiving DOX
(DOX, DOX þ MAG30, DOX þ MAG60), there was a considerable
decrease of body weight which occurred when DOX treatment was
given (data not shown). DOX, DOX þ MGR30 and DOX þ MGR60
also showed signs of general acute toxicity, including diarrhea, nose
and mouth bleeding, and pallor. However, body weight improved
and toxicity signs gradually subsided after DOX treatment ended.
Mortality rates were 0% in all groups .3.1. TNF-a mRNA expression level
TNF-a mRNA expression analysis results as depicted in Figure 1
show that DOX treatment increased TNF-a mRNA expression level
significantly (p < 0.05) in the DOX-only treated group compared
with the normal group (140%), whereas both groups receivingMAG
(DOX þ MAG30 and DOX þ MAG60) showed decreased TNF-a
mRNA expression level compared with the DOX only-treated group
(19.17% for DOXþMAG30 and 42.08% for DOXþMAG60). However,
the change was only statistically significant at group receivingMAG
60 mg/kg bw (p < 0.05).3.2. TNF-a level in brain tissues
DOX caused an increase in brain TNF-a level by 19.29%
compared to the normal group, as shown in Figure 2. It is of interest
that only co-treatment with MAG at a dose of 60 mg/kg bw could
significantly decrease brain TNF-a level compared to DOX-only
treated group (26.49%).3.3. Brain SOD activity
DOX caused a decrease in brain SOD activity level by 18.97%
compared to the normal group, as provided in Table 2. It is of in-
terest that only co-treatment with MAG at a dose of 30 mg/kg bw
could significantly increase brain SOD activity compared to DOX-
only treated group (92.20%).3.4. Brain MDA level
Brain level of MDAwas increased by 25.72% in DOX-only treated
group compared with normal group, although not statistically
significant. Table 2 also explains that coadministration of MAG at
doses of 30 and 60 mg/kg bw could significantly guard against the
increases of MDA level in brain tissue compared to DOX-only group
(by 39.62% and 47.50% accordingly).Figure 2. Effect of mangiferin (MAG) on doxorubicin (DOX)-induced alteration of brain
tumor necrosis factor (TNF)-a levels. Values are presented as mean ± standard devi-
ation, ap < 0.05 versus the normal group; bp < 0.05 versus the DOX group. Normal ¼
normal group, DOX ¼ doxorubicin 15 mg/kg bw, DOX þ MAG30 ¼ DOX 15 mg/kg bw
and MAG 30 mg/kg bw, DOX þ MAG60 ¼ DOX 15 mg/kg bw and MAG 60 mg/kg bw.
Table 2. Brain levels of MDA and SOD activity
Group MDA (nmol/mg prot) SOD (U/mg prot)
Control 7.97 ± 1.314 2.53 ± 1.229
DOX 10.02 ± 3.057 2.05 ± 1.162
DOX þ MAG30 6.05 ± 1.329* 3.94 ± 0.626*
DOX þ MAG60 5.26 ± 0.535* 3.04 ± 0.325
DOX ¼ doxorubicin; MAG ¼ mangiferin; MDA ¼ malondialdehyde; SOD ¼ super-
oxide dismutase.
Effect of MAG on DOX-induced alteration of brainMDA levels and brain SOD activity.
Values are presented as mean ± SD. Normal ¼ normal group, DOX ¼ doxorubicin 15
mg/kg bw, DOX þ MAG30 ¼ DOX 15 mg/kg bw and MAG 30 mg/kg bw, DOX þ
MAG60 ¼ DOX 15 mg/kg bw and MAG 60 mg/kg bw.
*p < 0.05 versus the DOX group.
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This research showed that a total dose of 15 mg/kg bw of DOX
was able to cause brain toxicity as evidenced by elevated brain TNF-
a gene expression and elevated brain TNF-a levels. Furthermore,
there was evidence of oxidative stress marked by increase of MDA
level and decrease of SOD activity, although SOD is not the only
important enzyme for antioxidant defense system. Treatment with
MAG at both 30 and 60 mg/kg bw was able to improve inflamma-
tion and oxidative stress induced by DOX administration. To the
best of our knowledge, this is the first study that revealed MAG
potency as a neuroprotective agent in DOX-induced brain damage.
In this study, signs of toxicity and body weight decrease were
observed in all groups receiving DOZ (DOX, DOX þ MAG30, and
DOX þ MAG60) after DOX treatment. However, the gradual
improvement of body weight that occurred after DOX treatment
ended with no difference between groups receiving MAG (DOX þ
MAG30 and DOX þ MAG60) and not receiving MAG (DOX). There
were no deaths observed in all groups. Considering body weight
and mortality rate data, it can be concluded that MAG seems to
have effect on general acute toxicity.
Acute side effects observed as results of DOX administrationwere
pallor, diarrhea and hemorrhage through mouth and nose. These
side effects occurred in all DOX-treated groups (DOX, DOXþMAG30,
and DOX þ MAG60). The coadministration of MAG together with
DOX did not prevent the occurrence of these acute side effects.
To understand the role of MAG in preventing brain damage
induced by DOX administration, this research conducted analysis
on brain TNF-a level, brain TNF-a mRNA expression, brain MDA
level and brain SOD activity. TNF-a is a cytokine which has a role in
congenital immune response (innate) as a response to several
stress. This substance is hypothesized as the cause of cognitive
damage on neurodegenerative diseases (McCoy and Tansey 2008;
Medeiros et al. 2007; McAlpine et al. 2009; Rubio-Perez and
Morillas-Ruiz 2012; Gonzalez-Scarano and Baltuch 1999). TNF-a
together with other cytokines has roles in acute and chronic
inflammation (Feghali and Wright 1997). This research found that
DOX group tended to experience an increase of TNF-a level in brain
tissues. In addition, a relative increase of TNF-a mRNA expression
occurred compared with the normal group. Statistically significant
differences of the TNF-a level and TNF-amRNA expression in brain
tissue samples between DOX group and control group were not
completely understood. The significant difference between TNF-a
level and TNF-a mRNA expression might be influenced by eukary-
otic elongation factor-2 which is an elongation control on TNF-a
translation (Gonzalez-Teran et al. 2013). The administration of MAG
decreased both the TNF-a level and the TNF-a mRNA expression
which were statistically significant at MAG 60 mg/kg bw of
administration dosage compared with the DOX group.
This research conducted evaluations on oxidative stress by
measuring SOD activity and MDA level on the brain tissues. SODenzymes,whichuptonowareknownto consist threedifferent kinds,
are among the antioxidant enzymes that transform O¡ to become
H2O2 (Misra and Fridovich 1972; McCord 2008; Blokhina et al. 2003;
Zelko et al. 2002). It hasbeenknownbefore that the increaseof TNF-a
causes the increase of iNOS expression, which in turn causes the in-
crease of O, leading to increased peroxynitrite, NF-kB activity
regulation, andotherprotein activity regulation (Alderton et al. 2001;
Bogdan 2001). SOD enzymes have a role in catching O radical,
preventing the formation of OH radical and more dangerous per-
oxynitrite radical (Krishnamurthy and Wadhwani 2012). The mea-
surements of SOD activity showed that on DOX group, there was a
tendency of decreased SOD activity compared to normal group.
Previous study conducted by Mohamed et al. (2011) discovered that
the decrease in SOD activity in the group inducted by DOX had a
significant difference compared to control group. The cause of this
significant difference was not precisely known. There is a possibility
that there areeffects ofNOto thedecreasingSODactivity, but this still
has to be proved. The coadministration of 30 mg/kg bw MAG
increased SOD activity significantly compared to DOX group. Mean-
while, coadministrationof 60mg/kgbwMAGshowedSOD levelwith
no significant difference compared with DOX group. This increase in
SOD might be influenced by cytokines which have roles in inflam-
mation, as known from previous research that SOD activity could be
increased by TNF-a, IL-1a, IL-1b, and interferon-g (Zelko et al. 2002).
MDA is a marker for lipid peroxidation (Krishnamurthy and
Wadhwani 2012). Reaction of lipid peroxidation is defined as a
reaction between polyunsaturated fatty acids. Lipid peroxide is
then decomposed into several molecules, including MDA (Alessio
2000). In this research, DOX group tended to experience an in-
crease in MDA. In previous study conducted by Mohamed et al.
(2011), it was known that the increase of MDA and decrease of
SOD activity in group inducted with DOX only was significant
compared to the control group. The difference between this
research and that previous research in particular may be caused by
the difference of sacrifice time of study animals: in this research,
study animals were sacrificed 4 weeks after DOX induction; in the
previous research, study animals were sacrificed 2 weeks after DOX
induction. The coadministration of MAG decreased MDA level
significantly compared to DOX-only group. Based on the SOD and
MDA analysis, it can be concluded that MAG has a role in decreasing
DOX-induced oxidative stress which occurs in brain tissue.
Based on evaluation of all parameters, this research shows that
there were no significant differences between coadministration of
DOX with 30 mg/kg MAG or 60 mg/kg MAG; although coadminis-
tration of 60 mg/kg MAG showed slightly better results. Based on
another previous research, 30 days administration of 500 mg/kg
MAG did not showmorphological changes nor death; hence, in the
next study, administration of MAG with higher dosage is very
possible (Sellamuthu et al. 2009). The increase in MAG dosing
should still consider the fact that dosage increase from 30 mg/kgBB
to 100 mg/kgBB will cause area under curve increase, which is not
linear, and also lengthening of half time (t1/2) (Lai et al. 2003).5. Conclusion
Based on the overall results, it can be concluded that MAG can
be a potential compound which can be used to prevent brain
damage caused by inflammation and oxidative stress on DOX-based
anticancer therapy.Acknowledgements
The authors express deep gratitude to all technicians in Animal
Housing Facility and researchers in Pharmacokinetics Laboratory,
The effect of mangiferin against brain damage 55Department of Pharmacology and Therapeutics, Universitas
Indonesia, for their assistance in this study.
Conflict of interest
The authors report that they have no conflict of interest.
Funding
This study was fully funded by a grant from DRPM UI, Depok,
Indonesia.
References
Abdel-Wahab M, El-Mahdy M, Abd-Ellah M, Helal G, Khalifa F, Hamada F. 2003.
Influence of p-coumaric acid on doxorubicin-induced oxidative stress in rat’s
heart. Pharmacol Res 48(5):461e5. http://dx.doi.org/10.1016/S1043-6618(03)
00214-7.
Agustini FD, Arozal W, Louisa M, Siswanto S, Soetikno V, Nafrialdi N, et al. 2015.
Cardioprotection mechanism of mangiferin on doxorubicin-induced rats: focus
on intracellular calcium regulation. Pharm Biol 6:1e9.
Alderton WK, Cooper CE, Knowles RG. 2001. Nitric oxide synthases: structure,
function and inhibition. Biochem J 357(Pt 3):593e615. http://dx.doi.org/
10.1042/0264-6021:3570593.
Alessio HM. 2000. Lipid peroxidation in healthy and diseased models: influence of
different types of exercise. In: Sen CK, Packer L, Hanninen OOP (Eds.). Handbook
of Oxidant and Antioxidants in Exercise. Amsterdam: Elsevier BV. pp. 115e27.
Aluise CD, Sultana R, Tangpong J, Vore M, St Clair D, Moscow JA, Butterfield DA.
2010. Chemo brain (chemo fog) as a potential side effect of doxorubicin
administration: role of cytokine-induced, oxidative/nitrosative stress in cogni-
tive dysfunction. In: Raffa RB, Tallarida RJ (Eds.). Chemo Fog: Cancer
Chemotherapy-Related Cognitive Impairment, Vol 678. New York: Springer.
pp. 147e56. http://dx.doi.org/10.1007/978-1-4419-6306-2.
Arozal W, Suyatna FD, Juniantito V, Rosdiana DS, Amurugam S, Aulia R, et al. 2015.
The Effects of Mangiferin (Mangifera indica L) in Doxorubicin-induced Car-
diotoxicity in Rats. Drug Res (Stuttg) 65(11):574e80.
Blokhina O, Virolainen E, Fagerstedt KV. 2003. Antioxidants, oxidative damage and
oxygen deprivation stress: a review. Ann Bot 91:179e94. http://dx.doi.org/
10.1093/aob/mcf118.
Bogdan C. 2001. Nitric oxide and the regulation of gene expression. Trends Cell Biol
11(2):66e75. doi: S0962-8924(00)01900-0 [pii].
Das J, Ghosh J, Roy A, Sil PC. 2012. Mangiferin exerts hepatoprotective activity
against D-galactosamine induced acute toxicity and oxidative/nitrosative stress
via Nrf2-NFkB pathways. Toxicol Appl Pharmacol 260(1):35e47. http://
dx.doi.org/10.1016/j.taap.2012.01.015.
Feghali CA, Wright TM. 1997. Cytokines in acute and chronic inflammation. Front
Biosci J Virtual Libr 2:d12e26.
Gilliam LAA, Moylan JS, Ferreira LF, Reid MB. 2011. TNF / TNFR1 signaling mediates
doxorubicin-induced diaphragm weakness TNF / TNFR1 signaling mediates
doxorubicin-induced diaphragm weakness. Am J Physiol Lung Cell Mol Physiol
300(1):L225e31. http://dx.doi.org/10.1152/ajplung.00264.2010.
Gonzales-Scarano F, Baltuch G. 1999. Microglia as mediators of inflammatory and
degenerative disease. Annu Rev Neurosci 22:219e40. http://dx.doi.org/10.1146/
annurev.neuro.22.1.219.
Gonzalez-Teran B, Cortes JR, Manieri E, Matesanz N, Verdugo A, Rodríguez ME, et al.
2013. Eukaryotic elongation factor 2 controls TNF-a translation in LPS-induced
hepatitis. J Clin Investig 123(1):164e78. http://dx.doi.org/10.1172/JCI65124.
Hortobagyi GN. 1997. Anthracyclines in the treatment of cancer. Drugs 54(4):1e7.
Ibrahim MA, Ashour OM, Ibrahim YF, El-Bitar HI, Gomaa W, Abdel-Rahim SR. 2009.
Angiotensin-converting enzyme inhibition and angiotensin AT(1)-receptor
antagonism equally improve doxorubicin-induced cardiotoxicity and nephro-
toxicity. Pharmacol Res 60(5):373e81.
Janelsins MC, Kohli S, Mohile SG, Usuki K, Ahles TA, Morrow GR. 2011. An update on
cancer- and chemotherapy-related cognitive dysfunction: current status. Semin
Oncol 38(3):431e8. http://dx.doi.org/10.1053/j.seminoncol.2011.03.014.AN.
Joshi G, Sultana R, Tangpong J, Cole MP, St Clair DK, Vore M, et al. 2005. Free radical
mediated oxidative stress and toxic side effects in brain induced by the anti
cancer drug adriamycin: insight into chemobrain. Free Rad Res 39(11):1147e54.
http://dx.doi.org/10.1080/10715760500143478.
Krishnamurthy P, Wadhwani A. 2012. Antioxidant enzymes and human health. In:
El-Missiry MA (Ed.). Antioxidant Enzyme. Croatia: InTech. pp. 1e17. http://
dx.doi.org/10.5772/2895.Lai L, Lin L, Lin J, Tsai T. 2003. Pharmacokinetic study of free mangiferin in rats by
microdialysis coupled with microbore high-performance liquid chromatog-
raphy and tandem mass spectrometry. J Chromatogr A 987:367e74.
Liu YW, Zhu X, Yang QQ, Lu Q, Wang JY, Li HP, et al. 2013. Suppression of methyl-
glyoxal hyperactivity by mangiferin can prevent diabetes-associated cognitive
decline in rats. Psychopharmacology. http://dx.doi.org/10.1007/s00213-013-
3061-5. 209.
Livak KJ, Schmittgen TD. 2001. Analysis of relative gene expression data using real-
time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 25(4):
402e8.
Marquez L, Garcia-Bueno B, Madrigal JLM, Leza JC. 2012. Mangiferin decreases
inflammation and oxidative damage in rat brain after stress. Eur J Nutr 51:
729e39. http://dx.doi.org/10.1007/s00394-011-0252-x.
McAlpine FE, Lee JK, Harms AS, Ruhn KA, Blurton-Jones M, Hong J, et al. 2009. In-
hibition of soluble TNF signaling in a mouse model of Alzheimer’s disease
prevents pre-plaque amyloid-associated neuropathology. Neurobiol Dis 34(1):
163e77. http://dx.doi.org/10.1016/j.nbd.2009.01.006.
McCord JM. 2008. Superoxide dismutase, lipid peroxidation, and bell-shaped dose
response curves. Dose-Response 6(3):223e38. http://dx.doi.org/10.2203/dose-
response.08-012.McCord.
McCoy MK, Tansey MG. 2008. TNF signaling inhibition in the CNS: implications for
normal brain function and neurodegenerative disease. J Neuroinflammation 5:
45. http://dx.doi.org/10.1186/1742-2094-5-45.
Medeiros R, Prediger RDS, Passos GF, Pandolfo P, Duarte FS, Franco JL, et al. 2007.
Connecting TNF-alpha signaling pathways to iNOS expression in a mouse model
of Alzheimer’s disease: relevance for the behavioral and synaptic deficits
induced by amyloid beta protein. J Neurosci Off J Soc Neurosci 27(20):5394e404.
http://dx.doi.org/10.1523/JNEUROSCI.5047-06.2007.
Misra HP, Fridovich I. 1972. The role of superoxide anion in the autoxidation of
epinephrine and a simple assay for superoxide dismutase. J Biol Chem 247(10):
3170e5.
Mohamed RH, Karam RA, Amer MG. 2011. Epicatechin attenuates doxorubicin-
induced brain toxicity: critical role of TNF-a, iNOS and NF-kB. Brain Res Bull
86:22e8. http://dx.doi.org/10.1016/j.brainresbull.2011.07.001.
Mukherjee S, Banerjee SK, Maulik M, Dinda AK, Talwar KK, Maulik SK. 2003. Pro-
tection against acute adriamycin-induced cardiotoxicity by garlic: role of
endogenous antioxidants and inhibition of TNF- a expression. BMC Pharmacol
3(16):1e9.
Osburg B, Peiser C, Domling D, Schomburf L, Ko YT, Voigt K, et al. 2002. Effect of
endotoxin on expression of TNF receptors and transport of TNF-alpha at the
blood-brain barrier of the rat. Am J Physiol Endocrinol Metab 283(5):E899e908.
http://dx.doi.org/10.1152/ajpendo.00436.2001.
Pal PB, Sinha K, Sil PC. 2013. Mangiferin, a natural xanthone, protects murine liver in
Pb(II) induced hepatic damage and cell death via MAP kinase, NF-kB and
mitochondria dependent pathways. PloS One 8(2):e56894. http://dx.doi.org/
10.1371/journal.pone.0056894.
Rubio-Perez JM, Morillas-Ruiz JM. 2012. A review: inflammatory process in Alz-
heimer's disease, role of cytokines. Sci World J 2012:756357. http://dx.doi.org/
10.1100/2012/756357.
Sellamuthu PS, Muniappan BP, Perumal SM, Kandasamy M. 2009. Anti-
hyperglycemic effect of mangiferin in streptozotocin induced diabetic rats.
J Health Sci 55(2):206e14. http://dx.doi.org/10.1248/jhs.55.206.
Szelenyi H, Kreuser ED, Keilholz U, Menssen HD, Keitel-Wittig C, Siehl J, et al. 2001.
Cyclophosphamide, adriamycin and dexamethasone (CAD) is a highly effective
therapy for patients with advanced multiple myeloma. Ann Oncol 12(1):105e8.
Tangpong J, Cole MP, Sultana R, Joshi G, Estus S, Vore M, et al. 2006. Adriamycin-
induced, TNF-alpha-mediated central nervous system toxicity. Neurobiol Dis
23(1):127e39. http://dx.doi.org/10.1016/j.nbd.2006.02.013.
Tannock IF, Ahles TA, Ganz PA, Van Dam FS. 2004. Cognitive impairment associated
with chemotherapy for cancer: report of a workshop. J Clin Oncol Off J Am Soc
Clin Oncol 22(11):2233e9. http://dx.doi.org/10.1200/JCO.2004.08.094.
Ujhazy P, Zaleskis G, Mihich E, EHrke MJ, Berleth ES. 2003. Doxorubicin induces
specific immune functions and cytokine expression in peritoneal cells. Cancer
Immunol Immunother CII 52(7):463e72. http://dx.doi.org/10.1007/s00262-003-
0391-x.
Usta Y, Ismailoglu UB, Bakkaloglu A, Orhan D, Besbas N, Sahin-Erdemli I, et al. 2004.
Effects of pentoxifylline in adriamycin-induced renal disease in rats. Pediatr
Nephrol 19(8):840e3.
Wefel JS, Saleeba AK, Buzdar AU, Meyers CA. 2010. Acute and late onset cognitive
dysfunction associated with chemotherapy in women with breast cancer.
Cancer 116(14):3348e56. http://dx.doi.org/10.1002/cncr.25098.
Zelko IN, Mariani TJ, Folz RJ. 2002. Superoxide dismutase multigene family: a
comparison of the CuZn-SOD (SOD1), Mn-SOD (SOD2), and EC-SOD (SOD3)
gene structure, evolution, and expression. Free Rad Biol Med 33(3):337e49.
